ARB Selection for Type 2 DM with CKD 3b, Hypertension, and Hyperphosphatemia
Start irbesartan 300 mg daily as your ARB of choice for this patient with type 2 diabetes, CKD stage 3b, and hypertension. 1
Rationale for ARB Therapy
ACE inhibitors or ARBs are the preferred first-line blood pressure agents for patients with diabetes, hypertension, and eGFR <60 mL/min/1.73 m² (which defines CKD stage 3b) because of proven benefits in preventing CKD progression. 2
RAS inhibition is strongly recommended for people with CKD and moderately-to-severely increased albuminuria with diabetes (Grade 1B recommendation). 3
The maximum tolerated dose should be used to achieve proven benefits, as clinical trials demonstrating efficacy used these doses. 3
Why Irbesartan Specifically
Irbesartan has the strongest evidence base for renoprotection in type 2 diabetic nephropathy:
The landmark IDNT trial demonstrated that irbesartan 300 mg daily reduced the risk of the primary composite endpoint (doubling of serum creatinine, end-stage renal disease, or death) by 20% compared to placebo and 23% compared to amlodipine, independent of blood pressure lowering effects. 1
Irbesartan reduced the risk of doubling serum creatinine by 33% versus placebo and 37% versus amlodipine (P<0.001), with a 23% lower relative risk of end-stage renal disease compared to both groups. 1
Proteinuria was reduced by 33% with irbesartan compared to only 6% with amlodipine and 10% with placebo, demonstrating superior antiproteinuric effects beyond blood pressure control. 4
These renoprotective effects were demonstrated specifically in patients with serum creatinine between 1.0-3.0 mg/dL and proteinuria >900 mg/day, matching your patient's CKD stage 3b profile. 4
Dosing and Monitoring
Start with irbesartan 300 mg once daily (the dose proven effective in clinical trials). 4, 1
Monitor within 2-4 weeks of initiation:
- Check blood pressure, serum creatinine, and serum potassium. 3
- Continue therapy unless serum creatinine rises by more than 30% within 4 weeks. 3
- Manage hyperkalemia with potassium-lowering measures rather than stopping the ARB when possible. 3
Managing Hyperphosphatemia
The hyperphosphatemia should be managed separately and does not contraindicate ARB therapy:
- Hyperphosphatemia in CKD 3b requires dietary phosphate restriction and potentially phosphate binders.
- ARB therapy does not directly worsen hyperphosphatemia and provides critical renoprotection that may slow CKD progression and subsequent worsening of mineral metabolism. 2
Additional Considerations
Continue the ARB even as kidney function declines:
- Maintain therapy even when eGFR falls below 30 mL/min/1.73 m² unless there is symptomatic hypotension, uncontrolled hyperkalemia despite treatment, or uremic symptoms requiring dose reduction. 3
Target blood pressure <130/80 mmHg to reduce cardiovascular mortality and slow CKD progression. 2
Do not combine with ACE inhibitors or direct renin inhibitors, as combination RAS blockade increases adverse events without additional benefit (Grade 1B recommendation against). 3
Consider adding SGLT2 inhibitor therapy if eGFR remains ≥20 mL/min/1.73 m² for additional kidney and cardiovascular protection (Grade 1A recommendation for patients with type 2 diabetes and CKD). 3